Clinical Trials

100 enrolled

Adenocarcinoma, Carcinoma, Digestive System Diseases, Digestive System Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial

NCT05014776 2026-02-24

Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer

17 enrolled 8 charts

Adenocarcinoma, Carcinoma, Pancreatic Neoplasms

NCT03504397 2026-02-13

Spotlight

565 enrolled 63 charts 1 FDA

Adenocarcinoma, Neoplasms, Stomach Neoplasms

NCT03653507 2026-02-06

GLOW

507 enrolled 65 charts 1 FDA

Adenocarcinoma, Neoplasms, Stomach Neoplasms

NCT06693128 2026-01-28

Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer

80 enrolled

Tumor-Agnostic

Adenocarcinoma

NCT06564844 2026-01-27

TROPION-Lung12

Phase 2/3 Active not recruiting

24 enrolled

Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung

NCT04208347 2026-01-23

Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer

580 enrolled

Tumor-Agnostic

Adenocarcinoma

NCT04704934 2026-01-12

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

490 enrolled

Phase 1 Active not recruiting

Adenocarcinoma, Stomach Neoplasms

NCT05273554 2026-01-12

A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma

15 enrolled

Tumor-Agnostic

Adenocarcinoma, Neoplasms

NCT07302451 2026-01-06

REDI-CaP

50 enrolled

Genitourinary

Adenocarcinoma, Prostatic Neoplasms

NCT02864992 2025-12-23

Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)